Q2 2026 Xvivo Perfusion AB Earnings Call Transcript
Key Points
- Xvivo Perfusion AB (XVIPF) reported a 36% organic top-line growth compared to the same quarter last year, indicating strong sales momentum.
- The company maintained a healthy EBITDA margin of 19%, demonstrating the scalability and profitability of its business model.
- Strong growth was observed in both the thoracic and abdominal segments, with significant contributions from lung and kidney sales.
- The company is expanding its sales force and commercial capabilities, particularly in North America, to drive future growth.
- Xvivo Perfusion AB (XVIPF) has a stable cash position with a neutral total cash flow for the third consecutive quarter, supporting its investment in growth initiatives.
- The services segment experienced a 25% decline in net sales, primarily due to lower organ recovery volumes.
- Gross margins in the abdominal segment were impacted by product mix and pricing conditions in certain markets, leading to a decrease from the previous year.
- Regulatory approval timelines remain uncertain, particularly for the heart and liver products in the US and Europe.
- The company faces increased competition in the liver segment in Europe, which could impact market share and pricing.
- Investments in sales force and regulatory activities are expected to drive higher operating expenses, potentially impacting short-term profitability.
Thank you so much. Good afternoon, everyone, and welcome to XVIVO's earnings call for the second quarter of 2026.
To get started, we go to slide 2 and today's presenters are me, Christoffer Rosenblad, CEO, calling in from Gothenburg, Sweden; and Kristoffer Nordstrom, CFO calling in from Denver in Colorado.
And with that, we can go over to slide 3, which is the Q2 financials at the glance, the Q2 shows the sales amount in line with the previous quarter Q1 and with a 36% organic top line growth compared to the same quarter last year. EBITDA was kept at a healthy level, resulting in a good operating cash flow.
For the third consecutive quarter, the total cash flow was neutral and hence, the cash position stable. Kristoffer Nordstrom, our CFO, will get into the details on sales, gross margin, cash flow and EBITDA later in this presentation.
If we look into the segments, both the track and abdominal segments are growing rapidly in both regions, North America and Europe. The lung market trend from Q4 last
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
